Hylomorph Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
13
- Latest Deal Type
-
Series B2
- Latest Deal Amount
-
$5M
- Investors
-
16
Hylomorph General Information
Description
Developer of healthcare biomaterials intended to optimize the interface between implantable medical devices and biological tissues. The company's bio-engineered implants prevent postoperative complications in implantable medical devices such as fibrosis, infection, and migration, deploy advanced methods combining biotech and surface micro-engineering to promote optimal interaction between human tissues and foreign implants and first indication for use in cardiac pacemakers and defibrillators and neurostimulators, enabling doctors to improve the quality of life of patients and the quality of care by healthcare professionals.
Contact Information
Website
www.hylomorph-medical.comCorporate Office
- Technoparkstrasse 1
- 8005 Zurich
- Switzerland
Corporate Office
- Technoparkstrasse 1
- 8005 Zurich
- Switzerland
Hylomorph Timeline
Hylomorph Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC (Series B2) | 01-Jul-2023 | $5M | Completed | Clinical Trials - General | ||
| 9. Later Stage VC (Series B) | 06-Dec-2021 | Completed | Clinical Trials - General | |||
| 8. Accelerator/Incubator | 31-Jan-2020 | Completed | Clinical Trials - General | |||
| 7. Secondary Transaction - Private | Completed | Clinical Trials - General | ||||
| 6. Grant | 09-Oct-2019 | Completed | Clinical Trials - General | |||
| 5. Early Stage VC (Series A) | 14-Sep-2018 | Completed | Clinical Trials - General | |||
| 4. Accelerator/Incubator | Completed | Startup | ||||
| 3. Accelerator/Incubator | Completed | Startup | ||||
| 2. Early Stage VC | 22-Aug-2016 | $114K | $114K | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Hylomorph Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred B2 | ||||||||
| Series B | ||||||||
| Series A | 515,866 | $0.111098 | $7 | $7 | 1x | $7 | 17.88% | |
| Ordinary | 111,111 | $0.111098 | $1.11 | $1.11 | 1x | $1.11 | 3.85% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Hylomorph Comparisons
Industry
Financing
Details
Hylomorph Competitors (3)
One of Hylomorph’s 3 competitors is Revivo BioSystems, a Venture Capital-Backed company based in Singapore, Singapore.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Revivo BioSystems | Venture Capital-Backed | Singapore, Singapore | ||||
| Cook Biotech | Private Equity-Backed | West Lafayette, IN | ||||
| Elutia | Formerly PE-Backed | Silver Spring, MD |
Hylomorph Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Hylomorph Patents
Hylomorph Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4362998-A1 | Method for preparing an implantable device | Pending | 29-Jun-2021 | ||
| US-20240350814-A1 | Method for preparing an implantable device | Pending | 29-Jun-2021 | ||
| EP-4161631-A1 | Insertion tool for pouches for ipgs | Active | 05-Jun-2020 | ||
| US-20230256255-A1 | Insertion tool for pouches for ipgs | Pending | 05-Jun-2020 | ||
| EP-4161631-B1 | Insertion tool for pouches for ipgs | Active | 05-Jun-2020 | A61N1/372 |
Hylomorph Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hylomorph Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Club degli investitori | Angel Group | Minority | ||
| Excellis | Venture Capital | Minority | ||
| Interconsult | Corporation | Minority | ||
| EFI Lake Geneva Ventures | Venture Capital | Minority | ||
| Geneva Funds | Mutual Fund | Minority |
Hylomorph FAQs
-
When was Hylomorph founded?
Hylomorph was founded in 2014.
-
Where is Hylomorph headquartered?
Hylomorph is headquartered in Zurich, Switzerland.
-
What is the size of Hylomorph?
Hylomorph has 13 total employees.
-
What industry is Hylomorph in?
Hylomorph’s primary industry is Biotechnology.
-
Is Hylomorph a private or public company?
Hylomorph is a Private company.
-
What is the current valuation of Hylomorph?
The current valuation of Hylomorph is .
-
What is Hylomorph’s current revenue?
The current revenue for Hylomorph is .
-
How much funding has Hylomorph raised over time?
Hylomorph has raised $18M.
-
Who are Hylomorph’s investors?
Club degli investitori, Excellis, Interconsult, EFI Lake Geneva Ventures, and Geneva Funds are 5 of 16 investors who have invested in Hylomorph.
-
Who are Hylomorph’s competitors?
Revivo BioSystems, Cook Biotech, and Elutia are competitors of Hylomorph.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
